Predictive factors for response to docetaxel in human breast cancers
- 29 June 2006
- journal article
- review article
- Published by Wiley in Cancer Science
- Vol. 97 (9), 813-820
- https://doi.org/10.1111/j.1349-7006.2006.00265.x
Abstract
Docetaxel has come into wide use recently for the treatment of breast cancer in neoadjuvant, adjuvant and metastatic settings. Docetaxel binds to beta-tubulin and causes kinetic abnormalities in the dynamics of microtubules by increasing their polymerization and inhibiting their depolymerization, resulting in elevated levels of microtubule formation. During metaphase, defective spindle formation induced by docetaxel activates the mitotic checkpoint and leads to cell cycle arrest, culminating in apoptosis. However, docetaxel is not effective for all breast cancers. For example, in metastatic settings, the response rate to docetaxel reportedly ranges from 30 to 50%. It is therefore very important to develop a diagnostic method with high accuracy for the prediction of sensitivity to docetaxel in order to avoid unnecessary treatment. Currently it is impossible to identify, before the initiation of therapy, the patients for whom docetaxel will be effective. Various biological parameters have been studied clinically for their ability to predict response to docetaxel, such as parameters related to: (1) efflux (p-glycoprotein) and metabolism (CYP3A4); (2) beta-tubulin (somatic mutation of beta-tubulin and changes in beta-tubulin isotypes levels); (3) cell cycle (HER2, BRCA1 and Aurora-A); and (4) apoptosis (p53, BCL2 and thioredoxin). More recently, gene expression profiling techniques have been used for the development of a prediction model for response to docetaxel. In the present paper, clinical studies that have been conducted recently to identify predictive factors for response to docetaxel are reviewed together with a presentation of our recent work in this field.Keywords
This publication has 49 references indexed in Scilit:
- Clinical response to neoadjuvant docetaxel predicts improved outcome in patients with large locally advanced breast cancersBreast Cancer Research and Treatment, 2005
- Individualized chemotherapy treatment for breast cancer: is it necessary? Is it feasible?Drug Resistance Updates, 2004
- Down-Regulation of Intratumoral Aromatase Messenger RNA Levels by Docetaxel in Human Breast CancersClinical Cancer Research, 2004
- Molecular-based prediction of early recurrence in hepatocellular carcinomaJournal of Hepatology, 2004
- Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapyEuropean Journal of Cancer, 2004
- Pharmacoproteomic analysis of prechemotherapy and postchemotherapy plasma samples from patients receiving neoadjuvant or adjuvant chemotherapy for breast carcinomaCancer, 2004
- The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27Journal of Clinical Oncology, 2003
- Genetic Analysis of the -Tubulin Gene, TUBB, in Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 2001
- BRCA1 and GADD45 mediated G2/M cell cycle arrest in response to antimicrotubule agentsOncogene, 2001
- Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes.JCI Insight, 1997